Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged MARINE
Can Amarin benefit from the GSK v. Teva decision regarding induced infringement for off-label sales?

Just when you think the Amarin saga to keep out generic competition is over, something else happens. In the latest development, the Federal Circuit issued a precedential decision in an unrelated case (GlaxoSmithKline v. Teva) that suggests that a generic could potentially be liable for inducing infringement of a patented indication, even though that indication has been carved out of the generic’s label. Will this decision benefit Amarin?

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, $AMRN, AMRN, GlaxoKlineSmith, $GSK, Teva, Apotex, Hikma, Dr. Reddy's, Vascepa, coreg, carvedilol, Federal Circuit, en banc, Rule 36, Cyclobenzaprine, Reyna, Bhatt, Dr. Bhatt, REDUCE-IT, MARINE, Zachary Silbersher, Silbersher Comments
Can Amarin’s patents protect Vascepa from generics?

Amarin Pharmaceuticals ($AMRN) will be going to trial soon to protect Vascepa® against generic competition.  Amarin has asserted 15 claims from six patents against ANDAs filed by Hikma, Dr. Reddy’s and Teva.  What are the issues to be addressed at trial?

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, $AMRN, AMRN, Vascepa, Hikma, Dr. Reddy's, Teva, $TEVA, MARINE, REDUCE-IT, generic, patent, Hatch-Waxman, Nevada, District of Nevada, hypertriglyceridemia, triglycerides, Epadel, Lovasa, LDL-C, EPA, Apo-B, apolipoprotein B, Zachary Silbersher, Silbersher Comments